TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06724042: First-in-human Phase 1a/b, Open-Label, Multicenter, Dose Escalation, Optimization and Expansion Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors

Sponsor: InSilico Medicine Hong Kong Limited · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 159 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT06724042 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06724042 Rescue Dossier →